N-Acetyl Larazotide
Also known as: N-Acetyl Larazotide, Larazotide
An N-acetylated analog of larazotide acetate, an octapeptide studied as a tight-junction regulator intended to reduce intestinal permeability (leaky gut). The N-acetyl modification is marketed to improve enzymatic stability of the parent peptide.
Last updated
Mechanism of Action
Larazotide acts locally in the gut lumen as a zonulin antagonist, blocking the zonulin signaling pathway that loosens epithelial tight junctions. By inhibiting tight-junction disassembly it reduces paracellular passage of antigens such as gliadin peptides across the intestinal barrier. It is not appreciably absorbed systemically, exerting effects at the apical surface of enterocytes. The acetylated derivative is proposed to resist brush-border peptidase degradation longer than the parent compound.
- Half-life
- Very short systemic half-life (acts locally in the gut lumen)
- Administration Routes
- oral
- Research Status
- Research Chemical
Reported Benefits
- Studied to tighten intestinal epithelial junctions and lower gut permeability
- Investigated as an adjunct for celiac disease symptom control
- May reduce passage of dietary and microbial antigens across the gut wall
- Acts locally with minimal systemic exposure
- Explored for gut-barrier support in inflammatory conditions
Potential Side Effects
- Headache reported in clinical trials of the parent peptide
- Gastrointestinal upset including nausea
- Abdominal discomfort
- Urinary tract infection signals noted in some trials
Common Dosing
In research and trial literature on larazotide acetate, oral doses around 0.25-0.5 mg taken before meals up to three times daily have been studied. Framed strictly for research use only and not as personal medical advice.
The dosing information above is aggregated from research literature and anecdotal community reports for educational purposes only. It is not a recommendation, prescription, or medical advice. Peptides are sold as research chemicals only and are not intended for human use.
Contraindications
- Not a validated treatment for any condition outside clinical trial settings
- Known hypersensitivity to the peptide
- Pregnancy and breastfeeding due to insufficient data
BPC-157
A synthetic peptide fragment derived from a protein found in gastric juice, studied for its broad tissue-healing and cytoprotective effects. Popular in research for tendon, ligament, muscle, and gut repair.
KPV
KPV is a tripeptide derived from the C-terminus of alpha-MSH that exerts anti-inflammatory effects without pigmentary activity. It is studied for gut inflammation, wound healing, and skin conditions.
Gut Inflammation Blend (BPC-157, KPV, PEA, Tributyrin)
A multi-component research blend combining the cytoprotective peptide BPC-157 with the anti-inflammatory tripeptide KPV plus fatty-acid mediators aimed at gastrointestinal mucosal repair. It is studied for its combined effects on gut-barrier integrity and local inflammation.
- View
Larazotide acetate for persistent symptoms of celiac disease despite a gluten-free diet: a randomized controlled trial
2015
- View
Larazotide acetate in patients with coeliac disease undergoing a gluten challenge: a randomised placebo-controlled study
2013
- View
A randomized, double-blind study of larazotide acetate to prevent the activation of celiac disease during gluten challenge
2012
- View
Larazotide acetate: a pharmacological peptide approach to tight junction regulation
2021